MedTrace Logo

Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative Option

NCT04926584 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-08-16

No results posted yet for this study

Summary

In a certified lung- cancer center, patients with NSCLC and a potentially curative stage (including patients with oligometastatic disease) are prospectively enrolled if curative treatment (either definitive radio-chemotherapy or resection) cannot be performed due to large tumor size or for functional reasons. For these patients, the multidisciplinary tumor board (MDB) recommends immuno-(chemo)therapy and re-evaluation. Response is assessed radiologically including PET-CT if indicated. After review of the MDB, patients receive either definitive curative treatment or palliative treatment.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

induction therapy

induction immuno-chemotherapy or immunotherapy prior to resection or definitive chemoradiotherapy

Sponsors & Collaborators

  • Klinikum Esslingen

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-15
Primary Completion
2024-12-31
Completion
2027-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04926584 on ClinicalTrials.gov